CIP
ALLO icon

Chartwell Investment Partners’s Allogene Therapeutics ALLO Stock Holding History

Chartwell Investment Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-31,781
Closed -$474K – 416
2021
Q4 		$474K Buy
31,781
+10,915
+52% +$193K 0.01% 411
2021
Q3 		$536K Hold
20,866
– – 0.02% 408
2021
Q2 		$544K Buy
20,866
+188
+0.9% +$5.36K 0.02% 404
2021
Q1 		$730K Sell
20,678
-1,110
-5% -$37.4K 0.02% 379
2020
Q4 		$550K Buy
21,788
+7,205
+49% +$235K 0.02% 396
2020
Q3 		$550K Hold
14,583
– – 0.02% 385
2020
Q2 		$624K Buy
+14,583
New +$527K 0.02% 364

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Chartwell Investment Partners's ALLO Position: Q1 2022 in Review

Chartwell Investment Partners sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 31,781 shares — an estimated $474K sold.

Chartwell Investment Partners first reported a position in ALLO in Q2 2020 and held it in 7 quarters. The position peaked at $730K in Q1 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

  • Chartwell Investment Partners reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 31,781 Allogene Therapeutics shares in Q1 2022, an estimated $474K.
  • Chartwell Investment Partners first reported a position in Allogene Therapeutics in Q2 2020 and held it in 7 quarters.
  • Chartwell Investment Partners's Allogene Therapeutics position peaked at $730K in Q1 2021.
  • 180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Chartwell Investment Partners's 13F filing for Q1 2022, filed 26 Apr 2022.